Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.

STUDY OBJECTIVES To determine whether long-term IV prostacyclin (PGI(2)) use improves exercise capacity in patients with primary pulmonary hypertension (PPH). DESIGN Cycle ergometry and the 6-min walk was used to evaluate the exercise performance of patients with PPH. The patients underwent serial exercise testing after starting continuous IV PGI(2) and were followed up for 19.5 +/- 7.5 months. Peak work, peak oxygen consumption (f1.gif" BORDER="0">O(2)), peak O(2) pulse, and distance walked in 6 min were used to evaluate performance. BACKGROUND PPH is characterized by medial hypertrophy and intimal proliferation of the pulmonary arterioles, leading to elevation of pulmonary artery pressure, right ventricular failure, and death. Palliative treatment consists of vasodilators, anticoagulants, cardiac glycosides, diuretics, and transplantation. PGI(2), a potent vasodilator and inhibitor of platelet aggregation, has been used for long-term treatment when conventional therapy has been unsuccessful. PATIENTS Sixteen patients with PPH (10 women, 6 men; mean age, 24 years). RESULTS At the initiation of PGI(2), peak work (+/- SD) was 35.5 +/- 11% of predicted; peak f1.gif" BORDER="0">O(2), 39 +/- 10.4%; peak O(2) pulse, 5.0 +/- 1.7 mL/min; and distance on the 6-min walk, 428 +/- 78 feet. At 18 to 27 months, peak work increased to 58.8 +/- 23% of predicted (p = 0.001), peak f1.gif" BORDER="0">O(2) increased to 52 +/- 15% of predicted (p = 0. 02), peak O(2) pulse increased to 7.1 +/- 3.0 mL/beat (p = 0.004), and performance on the 6-min walk increased to 526 +/- 62 feet (p = 0.001). There was a positive correlation between peak f1.gif" BORDER="0">O(2) and peak 6-min walk of 0.6 (p < 0.005) and between peak work and peak 6-min walk of 0.6 (p < 0.005). CONCLUSIONS Exercise capacity improved in our patients at up to 27 months of follow-up. Exercise testing is helpful in assessing the functional capacity of patients with PPH and may be useful in guiding therapy. Patients who deteriorate while receiving optimal conventional therapy should be considered for IV PGI(2) therapy.

[1]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[2]  M. Pasque,et al.  Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. , 1995, Circulation.

[3]  T. Higenbottam,et al.  Role of prostacyclin in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[4]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[5]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[6]  W. Gersony,et al.  Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. , 1991, Journal of the American College of Cardiology.

[7]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[8]  D. Rosenthal,et al.  Clinical exercise testing, 3rd ed , 1988 .

[9]  G. D'Alonzo,et al.  Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. , 1987, Chest.

[10]  R. Barst.  Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. , 1986, Chest.

[11]  G. D'Alonzo,et al.  Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. , 1986, The American review of respiratory disease.

[12]  A. Fishman,et al.  Exercise testing to evaluate patients with pulmonary vascular disease. , 2015, The American review of respiratory disease.

[13]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[14]  B. Groves,et al.  Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.

[15]  N. Jones.  Clinical Exercise Testing , 1982 .

[16]  D. Shannon,et al.  PROSTACYCLIN AND PROSTAGLANDIN E1 FOR SEVERE IDIOPATHIC PULMONARY ARTERY HYPERTENSION , 1980, The Lancet.

[17]  J. Dankert,et al.  HBsAg HAZARD IN BLOOD AND BONE-MARROW SMEARS , 1976, The Lancet.

[18]  G. M. Solov'ev,et al.  [Primary pulmonary hypertension]. , 1961, Terapevticheskii arkhiv.